Diagnosis and Treatment of Penile Cancer

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Genitourinary Oncology".

Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 827

Special Issue Editor


E-Mail Website
Guest Editor
Istituto Nazionale Tumori di Napoli, IRCCS “Fondazione G. Pascale”, Via M. Semmola, 80131 Naples, Italy
Interests: urology; uro-oncology; robotic surgery; renal cancer; prostate cancer; testis cancer; penile cancer; bladder cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Penile cancer is a rather rare malignancy and a potentially mutilating disease. Recent years have seen advancements in our understanding of the development of penile cancer, the risk factors associated with its onset, and the clinical and histological precursor lesions linked to this condition. Moreover, conservative and radical treatments can be disfiguring and may have an impact on sexual function, quality of life, social interactions, self-image, and self-esteem.

The aim of this Special Issue is to collect original articles, reviews, and meta-analyses from distinguished authors who have practical experience in researching innovations in the diagnosis, treatment, and prognosis of penile cancer.

The specific interests of this Special Issue include the following:

  • Epidemiological trends;
  • Risk factors;
  • Novel biomarkers;
  • Sexual function and quality of life post treatment;
  • Oncological follow-up.

We look forward to receiving your contributions.

Dr. Sisto Perdonà
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • penile cancer
  • surgical treatment
  • diagnosis
  • biomarkers
  • lymph-node status

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 2963 KiB  
Article
Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) in Penile Squamous Cell Carcinoma—No Evidence for a Role in Carcinogenesis
by August Fiegl, Olaf Wendler, Johannes Giedl, Nadine T. Gaisa, Georg Richter, Valentina Campean, Maximilian Burger, Femke Simmer, Iris Nagtegaal, Bernd Wullich, Simone Bertz, Arndt Hartmann and Robert Stoehr
Curr. Oncol. 2024, 31(10), 5752-5761; https://doi.org/10.3390/curroncol31100427 - 25 Sep 2024
Viewed by 431
Abstract
Penile squamous cell carcinoma (pSCC) is a rare malignancy with a global incidence ranging from 0.1 to 0.7 per 100,000 males. Prognosis is generally favorable for localized tumors, but metastatic pSCC remains challenging, with low survival rates. The role of novel biomarkers, such [...] Read more.
Penile squamous cell carcinoma (pSCC) is a rare malignancy with a global incidence ranging from 0.1 to 0.7 per 100,000 males. Prognosis is generally favorable for localized tumors, but metastatic pSCC remains challenging, with low survival rates. The role of novel biomarkers, such as tumor mutational burden (TMB) and microsatellite instability (MSI), in predicting the response to immune checkpoint inhibitors (ICIs) has been investigated in various cancers. However, MSI has not been observed in pSCC, limiting immunotherapy options for this patient subgroup. Elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) are a distinct form of genomic instability associated with deficient MSH3 expression, which has been proposed as a potential biomarker in several cancers. This study investigates EMAST and MSH3 expression in a cohort of 78 pSCC cases using PCR, fragment analysis and immunohistochemistry. For the detection of EMAST, the stability of five microsatellite markers (D9S242, D20S82, MYCL1, D8S321 and D20S85) was analyzed. None of the cases showed an instability. As for MSH3 immunohistochemistry, all analyzable cases showed retained MSH3 expression. These results strongly suggest that neither EMAST nor MSH3 deficiency is involved in the carcinogenesis of pSCC and do not represent reliable predictive biomarkers in this entity. Furthermore, these findings are in full agreement with our previous study showing a very low frequency of MSI and further support the thesis that EMAST and MSI are strongly interconnected forms of genomic instability. Further research is needed to explore novel therapeutic targets and predictive biomarkers for immunotherapy in this patient population. Full article
(This article belongs to the Special Issue Diagnosis and Treatment of Penile Cancer)
Show Figures

Figure 1

Back to TopTop